MaxCyte, Inc.
MXCT

$358.64 M
Marketcap
$3.40
Share price
Country
$-0.04
Change (1 day)
$5.55
Year High
$3.17
Year Low
Categories

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

marketcap

P/S ratio for MaxCyte, Inc. (MXCT)

P/S ratio as of 2023: 11.76

According to MaxCyte, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.76. At the end of 2022 the company had a P/S ratio of 12.55.

P/S ratio history for MaxCyte, Inc. from 2012 to 2023

P/S ratio at the end of each year

Year P/S ratio
2023 11.76
2022 12.55
2021 27.24
2020 45.13
2019 44.34
2018 52.21
2017 59.13
2016 46.44
2015 79.55
2014 103.15
2013 108.60
2012 146.06